NeoStem to Present its Autologous Adult Stem Cell VSEL Technology for the Treatment of Battlefield Wounds at The USU-HJF Military Medicine Symposium in Washington DC, September 23, 2010
NEW YORK, Sept. 22 /PRNewswire/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, today announced that the Company will be presenting its Autologous Adult Stem Cell VSEL™ Technology for the Treatment of Battlefield Wounds at The USU-HJF Military Medicine Symposium in Washington DC, September 23rd, 2010.
NeoStem has a worldwide exclusive license to VSEL™ Technology which uses very small embryonic-like stem cells, a heterogeneous population of stem cells found in adult bone marrow that have properties similar to those of embryonic stem cells. NeoStem has shown that very small embryonic-like stem cells can be mobilized into the peripheral blood, enabling a minimally invasive means for collecting what NeoStem believes to be an important population of stem cells that may have the potential to achieve the positive benefits associated with embryonic stem cells without the ethical or moral dilemmas or the potential negative effects associated with embryonic stem cells.
The Center for Public-Private Partnerships at the Henry M. Jackson Foundation for the Advancement of Military Medicine, along with the USU (Uniformed Services University of the Health Sciences), will present a symposium highlighting important advances in military medicine. The event will bring together a broad spectrum of participants, including representatives of the Military Health System and military leadership, federal agencies, private research institutions, philanthropists and charitable foundations, representatives of industry, and policymakers.
Panels will highlight advancements in research and clinical care, including:
- The state-of-the-science in regenerative medicine technologies and potential applications for wounded warriors
- The latest research on suicide prevention and traumatic stress among military veterans
- Community outreach to address psychological health challenges faced by service members and their families
The event is intended to foster collaboration and expand public-private partnerships to advance military medical research. The program will include opportunities for discussion and networking among participants.
The USU-HJF Military Medicine Symposium will be held on Thursday, September 23, 2010, at the Omni Shoreham Hotel located at 2500 Calvert Street, NW in Washington, DC. NeoStem will be exhibiting in the Blue Pre-Function Room its presentation on "Autologous Adult Stem Cell Solutions to Battlefield Wounds: Future Prospects for VSEL Technology". NeoStem's exhibit will be on display throughout the day from 7:30 am to 6:30 pm.
About NeoStem, Inc.
NeoStem, Inc. is engaged in the development of stem cell-based therapies, pursuit of anti-aging initiatives and building of a network of adult stem cell collection centers in the U.S. and China that are focused on enabling people to donate and store their own (autologous) stem cells for their personal use in times of future medical need. The Company is also the licensee of various stem cell technologies, including a worldwide exclusive license to VSEL™ Technology which uses very small embryonic-like stem cells, shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use. NeoStem's majority-controlled Chinese pharmaceutical operation, Suzhou Erye, manufactures and distributes generic antibiotics in China. For more information, please visit: http://www.neostem.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include the future of VSEL™ Technology and adult stem cells as a viable treatment option, about which no assurances can be given. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2010 as well as other periodic filings made with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.
Posted: September 2010